Michael Gordon Silverman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cholesterol, LDL | 3 | 2019 | 2374 | 0.590 |
Why?
|
Calcinosis | 4 | 2014 | 1467 | 0.580 |
Why?
|
Atherosclerosis | 6 | 2017 | 3401 | 0.570 |
Why?
|
Coronary Artery Disease | 9 | 2017 | 6363 | 0.500 |
Why?
|
Coronary Care Units | 1 | 2016 | 235 | 0.470 |
Why?
|
Hypolipidemic Agents | 3 | 2017 | 609 | 0.470 |
Why?
|
Body Temperature Regulation | 1 | 2015 | 286 | 0.450 |
Why?
|
Intubation, Intratracheal | 1 | 2020 | 1327 | 0.410 |
Why?
|
Resuscitation | 2 | 2019 | 661 | 0.400 |
Why?
|
Risk Reduction Behavior | 2 | 2016 | 1098 | 0.370 |
Why?
|
Hypothermia, Induced | 1 | 2015 | 756 | 0.350 |
Why?
|
Myocardial Revascularization | 1 | 2014 | 792 | 0.350 |
Why?
|
Glucosides | 3 | 2019 | 498 | 0.340 |
Why?
|
Triage | 2 | 2016 | 985 | 0.330 |
Why?
|
Heart Arrest | 2 | 2019 | 1494 | 0.330 |
Why?
|
Critical Illness | 1 | 2020 | 2704 | 0.290 |
Why?
|
Benzhydryl Compounds | 3 | 2019 | 900 | 0.290 |
Why?
|
Stroke Volume | 2 | 2019 | 5460 | 0.260 |
Why?
|
Cardiovascular Diseases | 5 | 2019 | 15394 | 0.250 |
Why?
|
Niacin | 3 | 2019 | 118 | 0.250 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 3227 | 0.250 |
Why?
|
Coronary Vessels | 6 | 2017 | 3072 | 0.250 |
Why?
|
Calcium | 5 | 2017 | 5722 | 0.240 |
Why?
|
Heart Failure | 7 | 2019 | 11593 | 0.220 |
Why?
|
Obesity | 4 | 2020 | 12869 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3077 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3197 | 0.210 |
Why?
|
Aspirin | 2 | 2014 | 3131 | 0.180 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2019 | 87 | 0.160 |
Why?
|
Coronary Angiography | 6 | 2017 | 4451 | 0.160 |
Why?
|
Cholesterol, HDL | 2 | 2017 | 1808 | 0.150 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2019 | 195 | 0.150 |
Why?
|
Benzoates | 1 | 2019 | 210 | 0.140 |
Why?
|
Pyrimidinones | 1 | 2019 | 383 | 0.130 |
Why?
|
Risk Factors | 13 | 2020 | 73716 | 0.130 |
Why?
|
Coronary Disease | 3 | 2014 | 5913 | 0.130 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 7982 | 0.120 |
Why?
|
C-Reactive Protein | 3 | 2015 | 3811 | 0.110 |
Why?
|
Aged, 80 and over | 8 | 2020 | 58559 | 0.110 |
Why?
|
Receptors, LDL | 1 | 2016 | 485 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5815 | 0.110 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 839 | 0.100 |
Why?
|
Middle Aged | 16 | 2020 | 219219 | 0.100 |
Why?
|
Myocardial Infarction | 3 | 2016 | 11422 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2019 | 12076 | 0.090 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2019 | 1373 | 0.090 |
Why?
|
Azetidines | 1 | 2011 | 140 | 0.080 |
Why?
|
Triglycerides | 2 | 2019 | 2450 | 0.080 |
Why?
|
Fatty Liver | 2 | 2013 | 776 | 0.080 |
Why?
|
Male | 18 | 2020 | 358227 | 0.080 |
Why?
|
Primary Prevention | 2 | 2014 | 1185 | 0.080 |
Why?
|
Humans | 27 | 2020 | 757650 | 0.080 |
Why?
|
Aged | 14 | 2019 | 167889 | 0.080 |
Why?
|
Incidence | 3 | 2017 | 21217 | 0.080 |
Why?
|
Body Mass Index | 4 | 2020 | 12870 | 0.080 |
Why?
|
Physical Fitness | 1 | 2013 | 732 | 0.080 |
Why?
|
Time Factors | 5 | 2019 | 39815 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1366 | 0.080 |
Why?
|
Cholesterol | 1 | 2017 | 2900 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6469 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4113 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3732 | 0.070 |
Why?
|
Severity of Illness Index | 3 | 2020 | 15782 | 0.070 |
Why?
|
United States | 7 | 2017 | 71907 | 0.070 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2180 | 0.070 |
Why?
|
Uric Acid | 1 | 2012 | 803 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3858 | 0.070 |
Why?
|
Female | 16 | 2019 | 389985 | 0.060 |
Why?
|
Heart | 1 | 2019 | 4382 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 5 | 2015 | 20499 | 0.060 |
Why?
|
Electrocardiography | 2 | 2016 | 6363 | 0.060 |
Why?
|
Chest Pain | 1 | 2012 | 1090 | 0.060 |
Why?
|
Recovery of Function | 1 | 2015 | 2970 | 0.060 |
Why?
|
Cost of Illness | 1 | 2013 | 1925 | 0.060 |
Why?
|
Population Surveillance | 1 | 2014 | 2599 | 0.060 |
Why?
|
Risk Assessment | 5 | 2019 | 23819 | 0.060 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1505 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39018 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2011 | 6293 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8601 | 0.040 |
Why?
|
Hospitalization | 2 | 2018 | 10633 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2020 | 79982 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8052 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2019 | 64242 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 106 | 0.040 |
Why?
|
Sex Factors | 3 | 2017 | 10497 | 0.040 |
Why?
|
Prognosis | 5 | 2019 | 29493 | 0.040 |
Why?
|
Aging | 1 | 2015 | 8650 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7366 | 0.030 |
Why?
|
Cohort Studies | 2 | 2016 | 41198 | 0.030 |
Why?
|
Cause of Death | 2 | 2019 | 3668 | 0.030 |
Why?
|
Inflammation | 1 | 2015 | 10718 | 0.030 |
Why?
|
Adult | 4 | 2020 | 219747 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9695 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2015 | 15209 | 0.030 |
Why?
|
Prevalence | 3 | 2017 | 15641 | 0.030 |
Why?
|
Linear Models | 2 | 2015 | 5857 | 0.030 |
Why?
|
Cerebral Infarction | 1 | 2018 | 982 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2019 | 2223 | 0.030 |
Why?
|
Prospective Studies | 2 | 2014 | 54108 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 960 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2015 | 584 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2019 | 2131 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14638 | 0.020 |
Why?
|
Brazil | 1 | 2013 | 1217 | 0.020 |
Why?
|
Diet, Mediterranean | 1 | 2015 | 736 | 0.020 |
Why?
|
Age Factors | 2 | 2015 | 18328 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9590 | 0.020 |
Why?
|
Myocardial Ischemia | 1 | 2018 | 2108 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2847 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3415 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2015 | 1878 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 3068 | 0.020 |
Why?
|
Exercise Test | 1 | 2013 | 2121 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12260 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12400 | 0.010 |
Why?
|
Fibrinolytic Agents | 1 | 2014 | 2070 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6231 | 0.010 |
Why?
|
Health Behavior | 1 | 2015 | 2615 | 0.010 |
Why?
|
Disease Management | 1 | 2014 | 2495 | 0.010 |
Why?
|
Life Style | 1 | 2015 | 3886 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14354 | 0.010 |
Why?
|
Emergency Medicine | 1 | 2012 | 1195 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9624 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10135 | 0.010 |
Why?
|
Hemorrhage | 1 | 2014 | 3399 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12047 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22008 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13464 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13222 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5951 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18123 | 0.010 |
Why?
|
Exercise | 1 | 2015 | 5788 | 0.010 |
Why?
|
Smoking | 1 | 2015 | 9036 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 25931 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 13952 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81107 | 0.010 |
Why?
|
Animals | 1 | 2019 | 167777 | 0.000 |
Why?
|
Young Adult | 1 | 2012 | 58764 | 0.000 |
Why?
|